Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lithium Americas Corp (LAC) vs Stryker Corporation (SYK) Price & Performance

Lithium Americas CorpTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Lithium Americas Corp vs Stryker Corporation — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 124.9× Lithium Americas Corp's market cap, and Stryker Corporation pays a 1.27% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Stryker Corporation for 21 Days on average.

LACSYK
Market Cap
$850.38M$106.24B
Volume
8,804,6372,982,001
Sector
Basic MaterialsHealth
52-Week High
$10.05$388.35
52-Week Low
$2.36$269.75
Typical Hold Time
27 Days21 Days
Enterprise Value
$1.19B$117.70B
Dividend Yield
—1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lithium Americas Corp

Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.

LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.

Stryker Corporation

Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.

The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LAC
25% Buy75% Sell
Avg holding period · 27 Days
SYK

No sentiment data available yet.

Top news

Latest headlines on both assets

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →